Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31077587 | 1.00 | LMNA (0.38) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL29475240 | 1.00 | LMNA (0.38) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL7850747 | 1.00 | LMNA (0.38) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL292475 | 1.00 | LMNA (0.38) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL2540704 | 1.00 | LMNA (0.38) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL23014995 | 1.00 | LMNA (0.38) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL31077494 | 1.00 | LMNA (0.38) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL31077654 | 1.00 | LMNA (0.38) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL31077631 | 1.00 | LMNA (0.38) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL850045 | 1.00 | LMNA (0.38) | LMNAALDH1A1HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120141817-A1 | THIN METAL NANOWIRES PRODUCED BY BIOTEMPLATING | MOROZOVA-ROCHE LUDMILLA (SE) | 2012-06-07 | — | — | US | claimed |
| EP-2132013-B1 | METHOD FOR THE MANUFACTURE OF THIN METAL NANOWIRES BY BIOTEMPLATING | MOROZOVA-ROCHE LUDMILLA (SE) | 2012-02-08 | — | — | EP | claimed |
| EP-2132013-A1 | THIN METAL NANOWIRES PRODUCED BY BIOTEMPLATING | Morozova-Roche, Ludmilla (SE) | 2009-12-16 | — | — | EP | claimed |
| WO-2008118094-A1 | THIN METAL NANOWIRES PRODUCED BY BIOTEMPLATING | MOROZOVA-ROCHE LUDMILLA (SE) | 2008-10-02 | — | — | WO | claimed |
| US-4455247-A | FLUORINATED ALCOHOL, AND A HIGH BOILING ELETRON DONATING ABSORBENT; | SANYO ELECTRIC CO., LTD. (JP) | 1984-06-19 | — | — | US | claimed |
| EP-0048281-A1 | COMPOSITION FOR ABSORPTION REFRIGERATOR | Sanyo Electric Co., Ltd (JP) | 1982-03-31 | — | — | EP | claimed |
| US-20250282818-A1 | SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION,INCORPORATED (US) | 2025-09-11 | — | — | US | disclosed |
| CN-115768839-B | Charge imparting agent, chargeable resin composition, and charged nonwoven fabric | 三洋化成工业株式会社 | 2024-05-03 | — | — | CN | disclosed |
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-23 | — | — | US | disclosed |
| WO-2023211883-A1 | SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023211883-A1 | SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-4183837-A1 | CHARGEABILITY IMPARTING AGENT, CHARGEABLE RESIN COMPOSITION AND CHARGED NONWOVEN FABRIC | Sanyo Chemical Industries, Ltd. (JP) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022132696-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-1935879-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-06-25 | — | — | EP | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| WO-2006025687-A1 | CHIRAL ALKOXY ALCOHOLS, CHIRAL 1 ,3-PHENYLENE-BΙS[4-(4-ALKOXY) PHENYLIMINOMETHYL] BENZOATES AND PROCESSES FOR PREPARATION THEREOF | DONGJIN SEMICHEM CO., LTD. (KR) | 2006-03-09 | — | — | WO | disclosed |
| US-5725798-A | CARBOXYLIC ESTERS FOR ELECTRICAL APPARATUS, SWITCHES AND CONTRAST | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1998-03-10 | — | — | US | disclosed |
| US-4455247-A | FLUORINATED ALCOHOL, AND A HIGH BOILING ELETRON DONATING ABSORBENT; | SANYO ELECTRIC CO., LTD. (JP) | 1984-06-19 | — | — | US | disclosed |
| EP-0048281-A1 | COMPOSITION FOR ABSORPTION REFRIGERATOR | Sanyo Electric Co., Ltd (JP) | 1982-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282818-A1 | SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF | PSMB10, PSMB1, PSMB5 | LMNA 1902/4885ALDH1A1 3864/4885HSD17B10 1046/4885 |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | LMNA 3909/4885ALDH1A1 3756/4885HSD17B10 836/4885 |
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | LMNA 3813/4885ALDH1A1 132/4885HSD17B10 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.